TABLE 1.
Phase of Development | Definition |
---|---|
I | Identify potential biomarkers in a preclinical setting. |
II | Assess the ability of the assay to distinguish between cases and controls. |
III | Analyze the ability of the assay to analyze preclinical disease. |
IV | Assess operating characteristics of biomarker‐based screening in the target population. |
V | Assess the impact of screening on cancer mortality. |